{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16"],"submitter":["Ren L"],"pubmed_abstract":["<h4>Introduction</h4>Although the transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab improves outcomes in unresectable HCC (uHCC), predictive tools are lacking. This study developed and validated a prognostic model for triple therapy efficacy.<h4>Methods</h4>A multicenter study enrolled uHCC patients receiving TACE-sintilimab-bevacizumab. Overall survival (OS) was the primary endpoint; a Cox model was developed and validated.<h4>Results</h4>This study enrolled 147 patients (training cohort: n = 92; validation cohort: n = 55). The optimal cutoff value for the fibrin degradation product-to-cholinesterase ratio*1000 (FCR) was determined as 0.8. Univariate and multivariate Cox regression analyses identified FCR, AST, AFP, and PVTT as independent OS predict"],"journal":["Frontiers in immunology"],"pagination":["1692632"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12685804"],"repository":["biostudies-literature"],"pubmed_title":["Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study."],"pmcid":["PMC12685804"],"pubmed_authors":["She S","Ren L","Fei R","Zhang X","Liao W","Cong X","Gao J","Chen H","Zhou Y","Chen D","Mu S"],"additional_accession":[]},"is_claimable":false,"name":"Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study.","description":"<h4>Introduction</h4>Although the transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab improves outcomes in unresectable HCC (uHCC), predictive tools are lacking. This study developed and validated a prognostic model for triple therapy efficacy.<h4>Methods</h4>A multicenter study enrolled uHCC patients receiving TACE-sintilimab-bevacizumab. Overall survival (OS) was the primary endpoint; a Cox model was developed and validated.<h4>Results</h4>This study enrolled 147 patients (training cohort: n = 92; validation cohort: n = 55). The optimal cutoff value for the fibrin degradation product-to-cholinesterase ratio*1000 (FCR) was determined as 0.8. Univariate and multivariate Cox regression analyses identified FCR, AST, AFP, and PVTT as independent OS predict","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-06T00:26:05.399Z","creation":"2026-05-24T03:11:13.639Z"},"accession":"S-EPMC12685804","cross_references":{"pubmed":["41376633"],"doi":["10.3389/fimmu.2025.1692632"]}}